WASHINGTON (AP) — Federal regulators are challenging patents on 20 brand name drugs, including the blockbuster weight-loss injection Ozempic, in the latest action by the Biden administration targeting industry practices that drive up pharmaceutical prices.
The Federal Trade Commission on Tuesday sent warning letters to 10 drugmakers, taking issue with patents on popular drugs for weight loss, diabetes, asthma and other reparatory conditions. The letters allege that certain patents filed by Novo Nordisk, GlaxoSmithKline, AstraZeneca and seven other companies are inaccurate or misleading.
Brand-name drugmakers use patents to protect their medicines and stave off cheaper, generic medicines. Most blockbuster drugs are protected by dozens of patents covering various ingredients, manufacturing processes and intellectual property. Generic drugmakers can only launch their own cheaper versions if the patents have expired or are successfully challenged in court.
Related articles:
Related suggestion:
Cardi B, Queen Latifah and The Roots to headline the BET Experience concerts in Los AngelesNHL says it set a singleTreasurer denies South Carolina Senate accusation he risked cyberattack in missing $1.8B caseBlake Griffin retires after a highUkraine prime minister calls for more investment in warBusiness boom: Record numbers of people are starting up new small businessesRory McIlroy debunks LIV Golf rumors. Greg Norman claims unanimous support during Masters tripButtler's unbeaten century helps Rajasthan beat Kolkata off final ballVenezuela closes embassy in Ecuador to protest raid on Mexican embassy thereREVEALED: Bartender, 33, 'who lured 19
2.9189s , 6574.8828125 kb
Copyright © 2024 Powered by US challenges 'bogus' patents on Ozempic and other drugs in effort to spur competition ,Global Grid news portal